Atrium Therapeutics, Inc. (RNA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$14.19-2.81%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · RNA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -43.2% |
| Our one-year growth estimate | diamond | -73.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 29.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
RNA — earnings miss
Dated 2026-08-13
of this Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Why it matters: High costs may show cash problems. This can affect future funding and operations.
Worry ifOperating costs are reported above $20 million for Q2.
Less concerning ifOperating costs stay below $20 million for Q2.
Why it matters: Cash burn trends will indicate how well Atrium is managing its expenses.
Worry ifCash burn decreases to below $30 million in Q2.
Less concerning ifCash burn increases above $31 million in Q2.
Why it matters: Initial data will provide insights into the efficacy of ATR 1072 for PRKAG2 syndrome. This could impact future funding and partnerships.
Supportive ifInitial trial data showing proof of concept will be released in late 2027.
Worry ifInitial trial data is delayed or shows no proof of concept.
Why it matters: Partnerships could speed up program development and help the company grow.
Supportive ifA new partnership with a big healthcare provider or research group is announced.
Worry ifNo new partnerships announced in the next quarter.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$171 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $438 loss on $10,000 · 4.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,241 loss on $10,000 · 32.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Enrollment in the Corventis trial is a key step for ATR 1072's clinical development. It shows progress in treating PRKAG2 syndrome.
Supportive ifAtrium enrolls the first participant in the Corventis Phase 1/2 trial by December 2026.
Worry ifNo participants are enrolled in the Corventis trial by the end of 2026.
Why it matters: Milestone payments show progress in Atrium's work with BMS. This helps the company's finances.
Supportive ifAtrium will get more milestone payments from Bristol Myers Squibb in the coming quarters.
Worry ifNo further milestone payments are received from BMS in the next quarters.
Why it matters: Initial data will show how well ATR 1072 works for PRKAG2 syndrome. This could prove the company's method.
Supportive ifInitial data from the Corventis trial shows proof of concept for ATR 1072.
Worry ifInitial data from the trial does not support proof of concept for ATR 1072.
Why it matters: Filing the IND for ATR 1086 will show progress in expanding Atrium's pipeline. This is important for future growth.
Supportive ifAtrium files the IND application for ATR 1086 in 2027.
Worry ifAtrium delays the IND filing for ATR 1086 beyond 2027.